Figure 2.

CHD1Li synergizes with TNBC therapies in MDA-MB-231 and HCC1937 tumor organoids. (A) Dose–response curves showing OTI-611’s synergistic effect when combined with PARPi and SOC chemotherapy as measured by IC₅₀ values in MDA-MB-231 tumor organoids treated for 72 h. (B) Dose–response curves showing OTI-611’s synergistic effect when combined with PARPi and SOC chemotherapy as measured by IC₅₀ values in HCC1937 tumor organoids treated for 72 h. Data are presented as the mean of two independent experiments ± S.E.M. See also Figure S2 for Bliss synergy scores quantification.